Evolution of immunosuppressive treatment modalities for renal transplant recipients

Robert R. Riggio, Rudy Haschemeyer, Jhoong Cheigh, Manikkam Suthanthiran, William Stubenbord, Luis Tapia, Kurt H. Stenzel

Research output: Contribution to journalArticle

Abstract

The addition of novel immunosuppressive agents and transfusion regimens to the therapy of human kidney transplantation has significantly improved the outcome of transplants that are performed today. At its inception, kidney transplantation quickly gained a foothold as an effective treatment modality for end-stage kidney disease because of the availability of living related donors and the drug azathioprine. That the procedure has established itself as acceptable, thus allowing for the development of the interventions to be discussed here, was largely due to our gradual understanding of how to use azathioprine safely, coupled with the fact that a viable alternative for prolonging life was not then available. When chronic hemodialysis emerged as a safe, effective, and readily available therapeutic regimen, the use of less noxious drugs and procedures in transplant recipients was virtually mandated. The interventions that subsequently gained a place in transplantation then were those that had relatively little down-side risk for the patient using azathioprine and corticosteroids as the reference standard. This procedural approach largely reduced the number of experimental immunosuppressive regimens initially deemed worthy of sustained clinical investigation. Often, however, the risk-benefit ratio approach proved to be difficult to assess. Indeed, the finding of associated side effects with dramatically effective drugs such as cyclosporin have presented new problems and decisions for the investigator to cope with.

Original languageEnglish
Pages (from-to)251-255
Number of pages5
JournalRenal Failure
Volume8
Issue number3-4
DOIs
Publication statusPublished - 1 Jan 1984
Externally publishedYes

Fingerprint

Azathioprine
Immunosuppressive Agents
Kidney
Kidney Transplantation
Pharmaceutical Preparations
Living Donors
Therapeutic Uses
Cyclosporine
Chronic Kidney Failure
Renal Dialysis
Adrenal Cortex Hormones
Therapeutics
Transplantation
Odds Ratio
Research Personnel
Transplants
Transplant Recipients

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Nephrology

Cite this

Riggio, R. R., Haschemeyer, R., Cheigh, J., Suthanthiran, M., Stubenbord, W., Tapia, L., & Stenzel, K. H. (1984). Evolution of immunosuppressive treatment modalities for renal transplant recipients. Renal Failure, 8(3-4), 251-255. https://doi.org/10.3109/08860228409115850

Evolution of immunosuppressive treatment modalities for renal transplant recipients. / Riggio, Robert R.; Haschemeyer, Rudy; Cheigh, Jhoong; Suthanthiran, Manikkam; Stubenbord, William; Tapia, Luis; Stenzel, Kurt H.

In: Renal Failure, Vol. 8, No. 3-4, 01.01.1984, p. 251-255.

Research output: Contribution to journalArticle

Riggio, RR, Haschemeyer, R, Cheigh, J, Suthanthiran, M, Stubenbord, W, Tapia, L & Stenzel, KH 1984, 'Evolution of immunosuppressive treatment modalities for renal transplant recipients', Renal Failure, vol. 8, no. 3-4, pp. 251-255. https://doi.org/10.3109/08860228409115850
Riggio, Robert R. ; Haschemeyer, Rudy ; Cheigh, Jhoong ; Suthanthiran, Manikkam ; Stubenbord, William ; Tapia, Luis ; Stenzel, Kurt H. / Evolution of immunosuppressive treatment modalities for renal transplant recipients. In: Renal Failure. 1984 ; Vol. 8, No. 3-4. pp. 251-255.
@article{0011d74b29c94f0f9eb1470ff23ae2f8,
title = "Evolution of immunosuppressive treatment modalities for renal transplant recipients",
abstract = "The addition of novel immunosuppressive agents and transfusion regimens to the therapy of human kidney transplantation has significantly improved the outcome of transplants that are performed today. At its inception, kidney transplantation quickly gained a foothold as an effective treatment modality for end-stage kidney disease because of the availability of living related donors and the drug azathioprine. That the procedure has established itself as acceptable, thus allowing for the development of the interventions to be discussed here, was largely due to our gradual understanding of how to use azathioprine safely, coupled with the fact that a viable alternative for prolonging life was not then available. When chronic hemodialysis emerged as a safe, effective, and readily available therapeutic regimen, the use of less noxious drugs and procedures in transplant recipients was virtually mandated. The interventions that subsequently gained a place in transplantation then were those that had relatively little down-side risk for the patient using azathioprine and corticosteroids as the reference standard. This procedural approach largely reduced the number of experimental immunosuppressive regimens initially deemed worthy of sustained clinical investigation. Often, however, the risk-benefit ratio approach proved to be difficult to assess. Indeed, the finding of associated side effects with dramatically effective drugs such as cyclosporin have presented new problems and decisions for the investigator to cope with.",
author = "Riggio, {Robert R.} and Rudy Haschemeyer and Jhoong Cheigh and Manikkam Suthanthiran and William Stubenbord and Luis Tapia and Stenzel, {Kurt H.}",
year = "1984",
month = "1",
day = "1",
doi = "10.3109/08860228409115850",
language = "English",
volume = "8",
pages = "251--255",
journal = "Renal Failure",
issn = "0886-022X",
publisher = "Informa Healthcare",
number = "3-4",

}

TY - JOUR

T1 - Evolution of immunosuppressive treatment modalities for renal transplant recipients

AU - Riggio, Robert R.

AU - Haschemeyer, Rudy

AU - Cheigh, Jhoong

AU - Suthanthiran, Manikkam

AU - Stubenbord, William

AU - Tapia, Luis

AU - Stenzel, Kurt H.

PY - 1984/1/1

Y1 - 1984/1/1

N2 - The addition of novel immunosuppressive agents and transfusion regimens to the therapy of human kidney transplantation has significantly improved the outcome of transplants that are performed today. At its inception, kidney transplantation quickly gained a foothold as an effective treatment modality for end-stage kidney disease because of the availability of living related donors and the drug azathioprine. That the procedure has established itself as acceptable, thus allowing for the development of the interventions to be discussed here, was largely due to our gradual understanding of how to use azathioprine safely, coupled with the fact that a viable alternative for prolonging life was not then available. When chronic hemodialysis emerged as a safe, effective, and readily available therapeutic regimen, the use of less noxious drugs and procedures in transplant recipients was virtually mandated. The interventions that subsequently gained a place in transplantation then were those that had relatively little down-side risk for the patient using azathioprine and corticosteroids as the reference standard. This procedural approach largely reduced the number of experimental immunosuppressive regimens initially deemed worthy of sustained clinical investigation. Often, however, the risk-benefit ratio approach proved to be difficult to assess. Indeed, the finding of associated side effects with dramatically effective drugs such as cyclosporin have presented new problems and decisions for the investigator to cope with.

AB - The addition of novel immunosuppressive agents and transfusion regimens to the therapy of human kidney transplantation has significantly improved the outcome of transplants that are performed today. At its inception, kidney transplantation quickly gained a foothold as an effective treatment modality for end-stage kidney disease because of the availability of living related donors and the drug azathioprine. That the procedure has established itself as acceptable, thus allowing for the development of the interventions to be discussed here, was largely due to our gradual understanding of how to use azathioprine safely, coupled with the fact that a viable alternative for prolonging life was not then available. When chronic hemodialysis emerged as a safe, effective, and readily available therapeutic regimen, the use of less noxious drugs and procedures in transplant recipients was virtually mandated. The interventions that subsequently gained a place in transplantation then were those that had relatively little down-side risk for the patient using azathioprine and corticosteroids as the reference standard. This procedural approach largely reduced the number of experimental immunosuppressive regimens initially deemed worthy of sustained clinical investigation. Often, however, the risk-benefit ratio approach proved to be difficult to assess. Indeed, the finding of associated side effects with dramatically effective drugs such as cyclosporin have presented new problems and decisions for the investigator to cope with.

UR - http://www.scopus.com/inward/record.url?scp=84907132100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907132100&partnerID=8YFLogxK

U2 - 10.3109/08860228409115850

DO - 10.3109/08860228409115850

M3 - Article

VL - 8

SP - 251

EP - 255

JO - Renal Failure

JF - Renal Failure

SN - 0886-022X

IS - 3-4

ER -